» Articles » PMID: 30402230

Synchronous Endometrial and Ovarian Cancer in Lynch Syndrome with a Germline Mutation: A Case Report

Abstract

Synchronous endometrial and ovarian cancer (SEOC) is a rare entity among gynecological cancers, which exhibits endometrioid histology in its early stages and generally has a good prognosis. However, diagnosis is difficult and recent reports have demonstrated that most clinically diagnosed cases of SEOC have clonally related cancers, indicating metastatic cancer. The association of SEOC with Lynch syndrome is also not clearly understood. We herein present the case of a 41-year-old SEOC patient with mutation. The endometrial cancer was an endometrioid adenocarcinoma and the ovarian cancer was mainly endometrioid, but also included a clear cell carcinoma with a borderline clear cell adenofibromatous component, indicating primary ovarian cancer. Both tumors exhibited microsatellite instability (MSI) and loss of expression of MSH2 and MSH6. The patient had a family history of colorectal and gastric cancers. Genetic analysis revealed a germline mutation in exon 6 of (c.1042C>T, p.Gln348*) and the patient was diagnosed with Lynch syndrome. This mutation has only been registered in one case in the InSiGHT variant databases and has not been reported in a gynecological tumor or SEOC to date. This case is a rare example of a patient with genetically diagnosed Lynch syndrome who also developed SEOC. This synchronous cancer is not common, but it may be caused by Lynch syndrome. Testing for MSI and immunohistochemistry for mismatch repair deficiency is necessary in cases with suspected SEOC.

Citing Articles

A Decade of Therapeutic Challenges in Synchronous Gynecological Cancers from the Bucharest Oncological Institute.

Simion L, Chitoran E, Cirimbei C, Stefan D, Neicu A, Tanase B Diagnostics (Basel). 2023; 13(12).

PMID: 37370964 PMC: 10297116. DOI: 10.3390/diagnostics13122069.


Somatic Tumor Profile Analysis in a Patient with Germline Mutation and Synchronous Ovarian and Uterine Carcinomas.

Huelsman K, Basil J, Sisson R, Lipe L, Mahon B, Draper D J Pers Med. 2021; 11(7).

PMID: 34357101 PMC: 8307264. DOI: 10.3390/jpm11070634.


Incidence of germline variants in Lynch syndrome-related genes among Japanese endometrial cancer patients aged 40 years or younger.

Makabe T, Yamagami W, Hirasawa A, Miyabe I, Wakatsuki T, Kikuchi M Int J Clin Oncol. 2021; 26(9):1767-1774.

PMID: 34115236 DOI: 10.1007/s10147-021-01953-5.


Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of "precursor escape"?.

Hsuan Weng C, Wu R, Chen S, Chen H, Tan K, Lee Y J Mol Med (Berl). 2021; 99(7):959-966.

PMID: 33768299 DOI: 10.1007/s00109-021-02064-4.


Microsatellite instability: a review of what the oncologist should know.

Li K, Luo H, Huang L, Luo H, Zhu X Cancer Cell Int. 2020; 20:16.

PMID: 31956294 PMC: 6958913. DOI: 10.1186/s12935-019-1091-8.

References
1.
Sjursen W, McPhillips M, Scott R, Talseth-Palmer B . Lynch syndrome mutation spectrum in New South Wales, Australia, including 55 novel mutations. Mol Genet Genomic Med. 2016; 4(2):223-31. PMC: 4799874. DOI: 10.1002/mgg3.198. View

2.
Norquist B, Harrell M, Brady M, Walsh T, Lee M, Gulsuner S . Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016; 2(4):482-90. PMC: 4845939. DOI: 10.1001/jamaoncol.2015.5495. View

3.
Millar A, Pal T, Madlensky L, Sherman C, Temple L, Mitri A . Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet. 1999; 8(5):823-9. DOI: 10.1093/hmg/8.5.823. View

4.
Sozen H, Vatansever D, Iyibozkurt A, Topuz S, Ozsurmeli M, Salihoglu Y . Clinicopathologic and survival analyses of synchronous primary endometrial and epithelial ovarian cancers. J Obstet Gynaecol Res. 2015; 41(11):1813-9. DOI: 10.1111/jog.12826. View

5.
Watson P, Vasen H, Mecklin J, Bernstein I, Aarnio M, Jarvinen H . The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008; 123(2):444-449. PMC: 2627772. DOI: 10.1002/ijc.23508. View